230 related articles for article (PubMed ID: 16106597)
21. Perseverance.
Prescrire Int; 2011 Feb; 20(113):54. PubMed ID: 21488600
[No Abstract] [Full Text] [Related]
22. New drug approval times and safety warnings in the United States and Canada, 1992-2011.
Rawson NS
J Popul Ther Clin Pharmacol; 2013; 20(2):e67-81. PubMed ID: 23650206
[TBL] [Abstract][Full Text] [Related]
23. Strong medicine.
Wadman M
Nat Med; 2005 May; 11(5):465-6. PubMed ID: 15875044
[No Abstract] [Full Text] [Related]
24. They are from the government and they really are here to help you.
Woosley RL
J Clin Pharmacol; 2008 Feb; 48(2):142-3. PubMed ID: 18199889
[No Abstract] [Full Text] [Related]
25. Institute of Medicine's new drug safety report: implications for Canada.
Cassels A
CMAJ; 2006 Dec; 175(12):1515-6. PubMed ID: 17146086
[No Abstract] [Full Text] [Related]
26. [The Medical Products Agency's preparations prior to the new EU regulation on children and drugs].
Johannesson M; Berglund EG
Lakartidningen; 2007 Jul 11-24; 104(28-29):2099. PubMed ID: 17702388
[No Abstract] [Full Text] [Related]
27. Time required for approval of new drugs in Canada, Australia, Sweden, the United Kingdom and the United States in 1996-1998.
Rawson NS
CMAJ; 2000 Feb; 162(4):501-4. PubMed ID: 10701383
[TBL] [Abstract][Full Text] [Related]
28. Cardiac repolarization and the safety of new drugs defined by electrocardiography.
Morganroth J
Clin Pharmacol Ther; 2007 Jan; 81(1):108-13. PubMed ID: 17186008
[TBL] [Abstract][Full Text] [Related]
29. Communicating with the FDA: the "third rail" of a new model for drug development.
Stanski DR; Orloff JJ
J Clin Pharmacol; 2008 Feb; 48(2):144-5. PubMed ID: 18199890
[No Abstract] [Full Text] [Related]
30. Effective global drug development strategy for obtaining regulatory approval in Japan in the context of ethnicity-related drug response factors.
Ichimaru K; Toyoshima S; Uyama Y
Clin Pharmacol Ther; 2010 Mar; 87(3):362-6. PubMed ID: 20107436
[No Abstract] [Full Text] [Related]
31. AIHP Kremers Award Address 2006. Pharmacovigilance and the missing denominator: the changing context of pharmaceutical risk mitigation.
Daemmrich A
Pharm Hist; 2007; 49(2):61-75. PubMed ID: 18368740
[No Abstract] [Full Text] [Related]
32. The risk we bear: the effects of review speed and industry user fees on new drug safety.
Olson MK
J Health Econ; 2008 Mar; 27(2):175-200. PubMed ID: 18207263
[TBL] [Abstract][Full Text] [Related]
33. Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma.
Eichler HG; Pignatti F; Flamion B; Leufkens H; Breckenridge A
Nat Rev Drug Discov; 2008 Oct; 7(10):818-26. PubMed ID: 18787530
[TBL] [Abstract][Full Text] [Related]
34. The lag from FDA approval to published cost-utility evidence.
Chambers JD; Thorat T; Pyo J; Neumann PJ
Expert Rev Pharmacoecon Outcomes Res; 2015 Jun; 15(3):399-402. PubMed ID: 25579324
[TBL] [Abstract][Full Text] [Related]
35. Relationship between pharmaceutical company user fees and drug approvals in Canada and Australia: a hypothesis-generating study.
Lexchin J
Ann Pharmacother; 2006 Dec; 40(12):2216-22. PubMed ID: 17132811
[TBL] [Abstract][Full Text] [Related]
36. Regulatory perspective on the importance of ADME assessment of nanoscale material containing drugs.
Zolnik BS; Sadrieh N
Adv Drug Deliv Rev; 2009 Jun; 61(6):422-7. PubMed ID: 19389437
[TBL] [Abstract][Full Text] [Related]
37. StatBite: New drug approvals in Japan: a comparison of review times and number of employees.
J Natl Cancer Inst; 2010 Feb; 102(3):150. PubMed ID: 20107162
[No Abstract] [Full Text] [Related]
38. Leveraging prior quantitative knowledge to guide drug development decisions and regulatory science recommendations: impact of FDA pharmacometrics during 2004-2006.
Wang Y; Bhattaram AV; Jadhav PR; Lesko LJ; Madabushi R; Powell JR; Qiu W; Sun H; Yim DS; Zheng JJ; Gobburu JV
J Clin Pharmacol; 2008 Feb; 48(2):146-56. PubMed ID: 18199891
[TBL] [Abstract][Full Text] [Related]
39. Success rates for new drugs entering clinical testing in the United States.
DiMasi JA
Clin Pharmacol Ther; 1995 Jul; 58(1):1-14. PubMed ID: 7628176
[No Abstract] [Full Text] [Related]
40. Promoting, improving and accelerating the drug development and approval processes.
Graul AI
Drug News Perspect; 2008; 21(1):36-43. PubMed ID: 18301808
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
